Theravance (TBPH) in Better Position Post Trelegy Deal, ampreloxetine Program Remains Key - Needham & Company Maintains Hold
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Hold rating on Theravance Biopharma (NASDAQ: TBPH), following the company's sale of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
